OncoMatch/Clinical Trials/Lung Cancer — Small Cell (SCLC)
Lung Cancer — Small Cell (SCLC) Clinical Trials
OncoMatch filters Lung Cancer — Small Cell (SCLC) trials by the molecular markers that determine eligibility — CD274, BRCA1, BRCA2, EGFR, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Lung Cancer — Small Cell (SCLC) trials
These are the molecular markers most commonly required or evaluated in Lung Cancer — Small Cell (SCLC) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Lung Cancer — Small Cell (SCLC) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Merck Sharp & Dohme LLC
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
OncoC4, Inc.
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Daiichi Sankyo
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
How OncoMatch finds Lung Cancer — Small Cell (SCLC) trials for you
AI reads the protocol
Every Lung Cancer — Small Cell (SCLC) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Lung Cancer — Small Cell (SCLC) and mark your biomarker results — CD274, BRCA1, BRCA2 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.